anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study will be prospective, interventional and will be conducted in two parallel groups selected on the basis of clinical diagnosis. It is planned to enroll 60 patients aged 18-70 years under outpatient nephrological care, with impaired excretory function of the kidneys (eGFR 20-60 ml / min / 1.73 m3), with proteinuria above 0.5-3 g / l in the morning urine sample , including 30 nondiabetic and 30 diabetic patients t.2 and 20 healthy control subjects (no microalbuminuria and no impaired renal function with eGFR\> 90 ml / min / 1.73m3). After the patients are familiarized with the objectives of the study and the informed consent signed, the following procedures will be performed.

After signing the consent, basic biochemical tests will be performed in both groups to assess the concentration of protein, albumin, calcium, phosphate, adenosine and creatinine in the morning urine sample, creatinine, calcium, phosphate, PTH, bacterial alkaline phosphatase (BAP), 1.25 vitamin D, sclerostins, FGF23, serum Klotho proteins, eGFR, plasma glucose. The tests will be repeated after 7 days of taking empagliflozin in a dose of 10 mg a day. On days 1 and 7, patients will be given an intravenous glucose 5% solution at a dose of 240 mg glucose / kg body weight in the first 15 minutes to induce a controlled hyperglycaemia state in the first 15 minutes, this will increase their blood glucose by 125 mg / dL in 15 minutes followed by 10-12 mg glucose / kg body weight, under glycemic control to maintain a concentration of 200 mg / dL ± 5% for 120 minutes. Stability of serum glucose levels during this period will be maintained by adjusting the rate of intravenous glucose infusion based on blood glucose measurements, every 15 minutes. After 2 hours of infusion, additional blood will be drawn for the determination of glucose and renal parameters and after 100 ml of urine for determination. adenosine, albumin and creatinine concentrations. In healthy subjects from the control group, the above basic blood and urine biochemical tests will be performed once.
Nutritional status has clinical relevance and is a target of guidance to parents of children with cystic fibrosis (CF). Growth is routinely monitored in CF clinics but there is no standardized way of assessing appetitive behaviors or parents' perceptions of their children's appetite. Greater understanding of these factors could improve clinical guidance regarding parent feeding behaviors. We therefore aimed to assess parent perceptions of child weight, and parent reports of child appetite using the Baby Eating Behavior Questionnaire (BEBQ), in a sample of infants and toddlers with CF, compared with a community sample. We additionally assessed relationships of parent perceptions of child weight with parent feeding behaviors in the sample with CF. Anthropometric and questionnaire data were collected for 32 infants and toddlers with CF, as well as 193 infants and toddlers drawn from RESONANCE, a community cohort study. Parents perceived children with CF to be lower in weight than their actual weight, to a greater extent than was evident in the community sample. Parents who perceived their children with CF to be underweight vs. right weight reported greater slowness in eating on the BEBQ. Parents perceived children with CF to have greater slowness in eating and lower enjoyment of food, compared to parents of children in the community sample, independent of sample differences in child weight, age, and sex. Our results demonstrate the potential utility of the BEBQ in a clinical sample and suggest it may be helpful for clinicians to assess parents' perceptions of their child's weight and appetite to promote a fuller understanding of the child's nutritional status, facilitate appropriate feeding behaviors and alleviate unnecessary concerns.
A total of 976 gliomas were enrolled in this study. First, in order to evaluate the diagnostic value of TERT promoter mutation in differ glioma subtypes, we conducted a retrospective cohort study included 753 frozen tissue samples of patients with different grades of glioma. According to WHO CNS5, all recommended alteration including IDH, 1p/19q, TERT, EGFRamp and 7+/10- were profiled using multiple approaches and a permanent diagnosis was obtained for each patient. Exploring the feasibility of the molecular pathology model of patients with glioma via retrospective research. Compare with the existing molecular pathology system, analyze the combination of IDH and TERT mutations and the feasibility of stratifying the prognosis of patients with glioma.

Moreover, to expend the application of the diagnostic algorithm to surgical practice, we developed a fast detection assay that could detect hotspot somatic mutations in IDH and TERT within 25 minutes and can discriminate TERT and IDH mutations from wild-type alleles with a minimum variant allele frequency (VAF) of 0.2% and 0.5%, respectively. We further validate the simplified diagnostic algorithm on frozen tissue of 223 patients with glioma in another retrospective cohort and performed this assay to evaluate the accuracy of the rapid assay.
The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia to allow the positioning of the transfix stitches necessary to the mesh fixation. Successively the retro-muscular rectum muscles plane will be prepared by the separation of the rectum muscles from the posterior rectum-muscles fascia. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched placed at the cardinal and inter-cardinal points. The prosthesis will be placed with a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt (JP) 10 suction drain will be placed under the prosthesis. A JP 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate- reabsorbable-time suture. Another JP 10 suction drain will be placed over the anterior fascia. No subcutaneous suture. Skin stapler or interrupted stitches will be used to close.
The chemical name of isosulfan blue is N-[4-[[4-(diethylamino)phenyl] (2,5-disulfophenyl) methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium hydroxide, inner salt, sodium salt. Isosulfan blue is a greenish blue color hygroscopic powder. Its structural formula is:  
  
Isosulfan blue injection 1% is a sterile, non-pyrogenic, aqueous dark blue color solution for subcutaneous administration. Phosphate buffer in water for injection is added in sufficient quantity to yield a final pH of 6.8 to 7.4. Each mL of solution contains 10 mg isosulfan blue, 6.6 mg sodium monohydrogen phosphate and 2.7 mg potassium dihydrogen phosphate. The solution contains no preservative. Isosulfan blue injection 1% is a contrast agent for the delineation of lymphatic vessels.
BACKGROUND: Migraine is an important disease due to its impact on global health. Due to association of neck pain with migraine, manual therapy (MT) often used in management. The aim of this study was to evaluate the effects of upper cervical spine MT on specific mechanisms including central sensitization (CS) and brainstem auditory evoked potentials (BAEPs) in subjects with migraine and neck pain.
METHODS: 30 subjects with migraine and neck pain (30 female, mean age 43.10 ± 8.13) were randomly assigned to a medication plus MT (MedMT) group, a medication plus sham manual therapy (sham MT) group, and a medication alone (Med) group. CS was evaluated using the Central Sensitization Inventory (CSI) and BAEP determined electrophysiologically in all subjects pre and post intervention. Subjects in MedMT and sham MT groups received either 4 sessions of MT or sham MT. All subjects received medication.
RESULTS: Subjects in MedMT group had a significant reduction in CSI score (P < 0.05) compare to the other 2 groups. For BAEPs, MedMT and sham MT groups had significantly decreased wave V latency on the right side (P < 0.05) compared to Med group.
DISCUSSION: Manual therapy plus medication may have beneficial effects in people with migraine and neck pain by normalizing central sensitization levels. Additionally, upper cervical manual therapy or sham manual therapy have demonstrable neurophysiological effects reflected by changes in the auditory transmission pathways in the brainstem. Further research is required to investigate the mechanisms of action of MT in migraine.
INTRODUCTION: Recent projections suggest a substantial rise in demand for revision total hip arthroplasties, emphasizing the need for optimized perioperative care. Various revision techniques, such as isolated acetabular or femoral component revisions and total replacements, have garnered attention. Further research is needed to establish the most effective strategies for improving clinical outcomes.
METHODS: This retrospective analysis utilized data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) Participant Use File from 2016 to 2021. The study aimed to compare clinical characteristics and 30-day outcomes among patients undergoing combined acetabular and femoral (A + F) revision,  acetabulum-only (A) revision, and femoral side-only (F) revision surgeries.
RESULTS: The analysis of 18,888 patients revealed crucial differences in preoperative and postoperative outcomes among various revision strategies. Specifically, there were notable variations in patient demographics, comorbidities, and emergency procedures. Postoperative data showed distinct rates of mortality, complications, and readmissions across the groups. Notably, femoral component revisions were associated with increased risks of mortality, transfusion, and urinary tract infections, underscoring the need for careful evaluation and consideration when opting for this revision approach.
CONCLUSION: The study's significance lies in its extensive patient cohort and multifaceted evaluation of revision strategies. Although consensus is lacking on single-component revisions, targeting the acetabulum component appears relatively safer. Continued research and individualized evaluations are crucial for refining revision strategies and optimizing outcomes in THA revisions.
PROBLEM TO BE SOLVED: To obtain a blood sugar value increase-suppressing agent suitable for preventing and curing of abnormal blood sugar value such as diabetes mellitus, containing an oligogalacturonic acid. SOLUTION: This blood sugar value increase-suppressing agent contains an oligogalacturonic acid of the formula and/or its salt ((n) is 0-20). Preferably, at least one kind selected from a compound of the formula or its salt is contained in the agent to make a medical composition, and the composition is used as a medicine or eating and drinking. This agent has slight side effect and can mildly reduce a blood sugar value. An administrating amount of the agent is 10-100,000mg for an adult per 1 day, in dividing to 1-several times and optimally is administered per os. The compound of the formula is readily obtained by hydrolyzing or acid-hydrolyzing pectin by an enzyme such as pectinase.
Accidental intravascular injection of ARTICADENT may be associated with convulsions, followed by central nervous system or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Dental practitioners who employ local anesthetic agents including ARTICADENT should be well versed in diagnosis and management of emergencies that may arise from their use. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. To avoid intravascular injection, aspiration should be performed before ARTICADENT is injected. The needle must be repositioned until no return of blood can be elicited by aspiration. Note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided.

Small doses of local anesthetics injected in dental blocks may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses. Confusion, convulsions, respiratory depression or respiratory arrest, and cardiovascular stimulation or depression have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. Patients receiving these blocks should be observed constantly. Resuscitative equipment and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded [see Dosage and Administration (2.1)].
The invention belongs to the technical field of biological medicines, and particularly relates to a thymoquinone derivative and application thereof in preparation of an AMPK activator and a medicine for treating breast cancer. The thymoquinone derivative provided by the invention is shown as a formula I. The invention also provides a synthetic method of the compound shown in the formula I. The compound (such as TQFL12) provided by the invention can obviously inhibit the growth, migration and invasion of breast cancer cells and has specific cytotoxicity on Triple Negative Breast Cancer (TNBC) cells. And the inhibition effect of TQFL12 on breast cancer cells is obviously stronger than that of Thymoquinone (TQ). Therefore, TQFL12 has potential as a drug for the treatment of breast cancer. In addition, TQFL12 activates AMPK/ACC signal pathway expression at the protein level by stabilizing AMPK α. Thus, TQFL12 can also act as an AMPK activator.
Maintaining a healthy lifestyle can extend life expectancy and improve a person's health status. In addition to physical activity and bad habits related to smoking and alcohol, diet is also a determining factor. Following a healthy diet pattern over time and supporting a healthy body weight contributes to reducing the risk of developing more severe complications associated with very common diseases such as chronic kidney disease (CKD), diabetes, or cardiovascular diseases. The 2015-2020 Dietary Guidelines for Americans promote the adoption of fat-free or low-fat diets and discourage the consumption of foods with added sugar and solid fats, such as ice creams and other frozen desserts. On the other hand, ice cream, from a nutritional and healthy point of view, can be considered a possible food choice, due to its greater palatability and high nutritional content, but its consumption must be scheduled in a balanced diet. In this retrospective study, 36 patients with chronic renal failure were enrolled. Two different diets were proposed (A and B). In Diet B, lemon sorbet was added twice a week as an alternative food to replace fruit or snacks making the diet more varied and palatable. Nutritional status and biohumoral, immunological, and blood parameters were evaluated after 6 months. A statistical analysis shows a significant inter-group difference in creatinine and azotemia between T0 and T1. Intra-group significant differences were found in lymphocytes (p = 0.005) and azotemia (p < 0.001) in Diet A, and in azotemia (p < 0.001) and transferrin (p < 0.001) in Diet B. The results indicated that ice cream represented a good alternative food in both groups of patients regarding nutritional values and patient satisfaction. Furthermore, the treatment with ice cream allowed for better control of azotemia, maintaining stable levels even in patients with advanced CKD. This study concludes that ice cream could exert beneficial effects in addition to CKD patients' dietary regimens.
Obstructive sleep apnea/hypopnea syndrome (OSAHS) is a disorder characterized by recurrent upper airway collapse during sleep. Clinical consequences as increased cardiovascular events and automobile accidents were noted. Polysomnography is diagnostic while continuous positive airway pressure (CPAP) is the standard treatment. The adherence of CPAP treatment remained suboptimal, between 29 to 83%. In selected cases, alternative treatments were considered useful. However, how to choose candidates is still an issue.

Sleep endoscopy has been introduced since 1991 to allow direct visualization of the upper airway under sleep simulation. It predicts better outcome in non-adherent OSAHS patients who received alternative treatment. However, the ideal dose, drug, and sedative depth were not known.

Bispectral Index (BIS) monitor is a noninvasive neurophysiological monitoring device that been introduced since late 1990's. By applying a sensor to the forehead, the BIS obtained electroencephalograms(EEG) and electromyograms(EMG) which were transformed into simplified scaled numbers through 0-100. It has been applied in the real time monitor of anesthesia depth during operation or recovery, monitor of sleep in critical illness patients and gastrointestinal endoscopy sedation.

This study focuses on CPAP non-adherent patients. It evaluates the upper airway collapsibility in awake and two different sedative levels, BIS 65-75 (light sedation) and BIS 50-60(deep sedation). Conscious sedation will be achieved by propofol pump infusion. No benzodiazepam or opioid are used to avoid the effect of upper airway muscle tone and respiratory drive. The patency over the velopharynx, oropharynx, larynx, and hypopharynx will be recorded. Specific obstruction patterns such as tongue base retraction, epiglottis anterior-posterior decent, omega-shaped epiglottis,and bilateral arytenoids anterior drawing will also be recorded. The correlation of the upper airway collapsibility between sedative depth and sleep stages (ex. NREM vs. REM) will be evaluated. Besides, mandible advancement will be done under deep sedation. The response will guide further treatment choice for those CPAP non-adherent patient.
PROBLEM TO BE SOLVED: To obtain the subject loxoprofen sodium solid preparation that can reduce the strong adhesion of loxoprofen sodium and shows excellent stability after manufacturing by spraying the granules containing loxoprofen sodium and saccharides with a solution containing cellulosic preparation material and drying them. SOLUTION: The granules containing (A) loxoprofen sodium and (B) saccharides as lactose and the like are sprayed with a solution (D) containing a cellulosic preparation material, preferably hydroxypropyl-cellulose of a low substitution degree, preferably with particle sizes of <=100 μm. The solvent for the component (D) is preferably water and/or an alcohol, the viscosity of the component kD is preferably 1-200 cP. In case the component C is a low- substitution degree hydroxypropylcellulose, 100 pts.wt. of the granules are preferably sprayed with 6-10 pts.wt. of the hydroxypropylcellulose. This pharmaceutical preparation is useful for treatment of rheumatoid arthritis, arthrosis deformans, low back pain and the like.
PURPOSE:To efficiently and rapidly separate and remove an exothermic substance in water by bringing the water into contact with an adsorbent based on acidic polyamino acid having alkylenediamine in the side chain, CONSTITUTION:Water contg. an exothermic substance is brought into contact with an adsorbent based on acidic polyamino acid having alkylenediamine in the side chain and the exothermic substance is adsorbed on the adsorbent. The acidic polyamino acid is alkyl ester of polyglutamic acid or polyaspartic acid and is used after carboxyl groups in the side chain are amidated with alkylenediamine. Ethylenediamine or 1,3-propanediamine may be used as the alkylenediamine and the alkylenediamine content of the adsorbent is preferably regulated to 1-5 meq/g. The adsorbent is packed into a column and washed with a proper buffer soln. Water contg. an exothermic substance is passed through the column and the passed fraction is recovered. Thus, water freed of the exothermic substance can be obtd.
The most commonly reported (>15%) adverse experiences occurred with similar frequencies in the pamidronate disodium-and placebo-treatment groups, and most of these adverse experiences may have been related to the underlying disease state or cancer therapy.

Of the toxicities commonly associated with chemotherapy, the frequency of vomiting, anorexia, and anemia were slightly more common in the pamidronate disodium patients whereas stomatitis and alopecia occurred at a frequency similar to that in placebo patients. In the breast cancer trials, mild elevations of serum creatinine occurred in 18.5% of pamidronate disodium patients and 12.3% of placebo patients. Mineral and electrolyte disturbances, including hypocalcemia, were reported rarely and in similar percentages of pamidronate disodium-treated patients compared with those in the placebo group. The reported frequencies of hypocalcemia, hypokalemia, hypophosphatemia, and hypomagnesemia for pamidronate disodium-treated patients were 3.3%, 10.5%, 1.7%, and 4.4%, respectively, and for placebo-treated patients were 1.2%, 12%, 1.7%, and 4.5%, respectively. In previous hypercalcemia of malignancy trials, patients treated with pamidronate disodium (60 or 90 mg over 24 hours) developed electrolyte abnormalities more frequently (see ADVERSE REACTIONS, Hypercalcemia of Malignancy). 

Arthralgias and myalgias were reported slightly more frequently in the pamidronate disodium group than in the placebo group (13.6% and 26% vs 10.8% and 20.1%, respectively).

In multiple myeloma patients, there were five pamidronate disodium-related serious and unexpected adverse experiences. Four of these were reported during the 12-month extension of the multiple myeloma trial. Three of the reports were of worsening renal function developing in patients with progressive multiple myeloma or multiple myeloma-associated amyloidosis. The fourth report was the adult respiratory distress syndrome developing in a patient recovering from pneumonia and acute gangrenous cholecystitis. One pamidronate disodium-treated patient experienced an allergic reaction characterized by swollen and itchy eyes, runny nose, and scratchy throat within 24 hours after the sixth infusion.

In the breast cancer trials, there were four pamidronate disodium-related adverse experiences, all moderate in severity, that caused a patient to discontinue participation in the trial. One was due to interstitial pneumonitis, another to malaise and dyspnea. One pamidronate disodium patient discontinued the trial due to a symptomatic hypocalcemia. Another pamidronate disodium patient discontinued therapy due to severe bone pain after each infusion, which the investigator felt was trial-drug-related.
The invention provides a lysosome-targeted iridium complex, and a preparation method and application thereof. Comprising iridium complex cations and coordination anions with structures shown in a formula I or a formula II. The iridium complex prepared by the invention has novel structure, lysosome targeting property and phosphorescence characteristic, can realize phosphorescence imaging of cells and tissues, can be used as a photosensitizer, can generate active oxygen under illumination, and is used for photodynamic therapy of tumors. Under weak acidic conditions, the complexThe phosphorescence of the compound is significantly enhanced, and the ability to generate singlet oxygen and catalyze NADH is also increased, thus having a more effective killing ability against lysosomes and tumors. The preparation method has the advantages of simple preparation process, high yield, good repeatability and the like. The iridium complex prepared by the invention can be used for biological imaging and photodynamic therapy of tumors.